How Long Can You Take Steroids for Polymyalgia?

Most people with polymyalgia rheumatica (PMR) take corticosteroids for one to three years, but a large minority end up on them much longer. One study found a median treatment duration of about 37 months, with an estimated 40 percent of patients still needing steroids beyond four years.¹ The answer to “how long” depends less on a fixed calendar and more on how your body responds to tapering, because PMR is a disease defined by relapses.

What the Typical Treatment Course Looks Like

PMR treatment almost always starts with prednisone (or prednisolone) at a dose of about 15 mg per day, sometimes a little more. Most people feel dramatically better within a few days, which is part of how doctors confirm the diagnosis. From there, the goal is a slow, steady taper: reducing the dose to roughly 7.5 to 10 mg by two months, and eventually aiming for a maintenance dose around 7.5 mg by six to nine months.² After that, most tapering schedules continue dropping the dose by tiny increments, sometimes as little as 1 mg every few weeks or even per month, until you can stop entirely.

In a follow-up survey of PMR patients, those who had successfully stopped steroids reported taking them for an average of about 20 months total.³ That represents the faster end of the spectrum. A substantial group never reaches that finish line on the first attempt: about 40 percent of respondents in that same survey were still taking steroids at follow-up, at a median daily dose of 5 mg.³ The disease itself typically resolves in one to two years, but up to half of patients need treatment for longer than two years because symptoms return during tapering.⁴

Researchers have described what looks like two distinct patient populations: one group whose disease is relatively limited and who can stop steroids within about two years, and another group that requires long-term therapy stretching well beyond that.¹ There is no reliable test at diagnosis to tell you which group you belong to, which is one of the frustrating realities of this condition.

Why Relapses Keep People on Steroids Longer

Relapses are the main reason people with PMR stay on steroids far beyond what they initially expected. A meta-analysis pooling data from seven studies found that roughly 43 percent of patients experienced at least one relapse within the first year of treatment.⁵ Other estimates suggest that about half of all PMR patients relapse at some point during their course.⁶

Relapses tend to happen at predictable moments during the taper. They are especially common when the prednisone dose drops below 5 to 7.5 mg per day, which is the range where many people feel they are almost done.⁶ A relapse means symptoms return (shoulder and hip stiffness, pain, fatigue), and the standard response is to bump the dose back up and start tapering again more slowly. Each relapse adds months to the total treatment time. For some people this happens repeatedly, which is how treatment stretches from the hoped-for one year into three, four, or five years.

The speed of the taper itself appears to be the biggest modifiable factor influencing relapse risk. Cutting the dose too quickly is the most commonly identified trigger. There is also a genetic component: certain immune-related gene variants have been associated with a higher likelihood of flaring, though genetic testing is not used in routine management.⁶ In practice, people who self-manage their steroid dose by adjusting it on their own based on symptoms, rather than following a schedule agreed upon with their doctor, are more likely to still be on treatment at follow-up.³ That suggests structured tapering with regular medical oversight leads to better outcomes than adjusting your own dose when things flare.

What Happens to Your Body on Long-Term Steroids

Steroids work remarkably well for PMR, but every month on them adds to the cumulative toll on your body. A retrospective study of PMR patients on long-term low-dose glucocorticoids found that side effects became noticeably more frequent after two years of treatment. The most common problems were osteoporosis, fragility fractures, and high blood pressure. Diabetes, heart attacks, and stroke also occurred at elevated rates.⁷

Both the duration and the total cumulative dose of steroids matter, though not always for the same complications. Longer treatment duration was independently linked to osteoporosis and high blood pressure, while the cumulative dose (the total amount of prednisone your body has absorbed over the entire treatment course) was independently associated with fragility fractures.⁷ In practical terms, this means that even a low daily dose becomes risky if you are on it for years, because the body accumulates damage from both the daily exposure and the running total.

Real-world data from England put the fracture risk in stark terms: people with PMR have a 63 percent higher risk of fracture compared with matched controls of the same age and sex, and that risk is dose-related.⁸ About a quarter of patients in that dataset were still on glucocorticoids beyond four years.⁸ Other common side effects of prolonged steroid use include weight gain, thin and fragile skin, easy bruising, cataracts, mood changes, and difficulty sleeping. These tend to be dose-dependent: reducing even from 7.5 mg to 5 mg makes a real difference, which is one reason doctors push for the lowest possible maintenance dose.

Protecting Your Bones During Treatment

Because fracture risk is one of the most serious consequences of long-term steroid use, bone protection comes up early in PMR management. Most guidelines recommend that anyone expected to be on glucocorticoids for three months or more should be assessed for osteoporosis risk and considered for a bone-protective medication, usually a bisphosphonate. Calcium and vitamin D supplements are standard as well.

The real-world picture is less tidy than the guidelines suggest. One cohort study of PMR patients found that bisphosphonate prescriptions were associated with higher fracture rates at 12 months, but the researchers cautioned against reading that as a failure of the drugs. The most likely explanation is confounding by indication: patients who already had the highest fracture risk were the ones prescribed bisphosphonates in the first place. And oral bisphosphonates take several months to meaningfully improve bone density, so they may not prevent fractures that were already in motion when treatment started.⁹ The practical takeaway is that bone protection should ideally start at the same time as steroid treatment, not after a fracture scare.

Steroid-Sparing Options

Given the risks of prolonged steroid use, both doctors and patients are naturally interested in drugs that could replace some or all of the steroid burden. Two main candidates have been studied: methotrexate and tocilizumab.

Methotrexate

Methotrexate is widely used in rheumatoid arthritis and is inexpensive, so it was a natural candidate to test in PMR. The results have been mixed at best. An early randomized trial found no differences between methotrexate and placebo in time to remission, duration of remission, number of relapses, or total steroid dose.¹⁰ A more recent single-center study confirmed that methotrexate did not significantly reduce the cumulative steroid dose in the overall PMR population. However, a subgroup analysis told a different story: among patients whose PMR was resistant to standard steroid tapering, adding methotrexate cut the total steroid exposure by over 1,300 mg over two years and dramatically increased the rate of successful steroid discontinuation compared with steroids alone.¹¹

The emerging picture is that methotrexate probably does not help most PMR patients, but it may be genuinely useful for the subset who keep relapsing and cannot get off steroids. Patient selection turns out to be the key variable.

Tocilizumab

Tocilizumab, an injectable biologic drug that blocks a specific inflammatory signal (interleukin-6), has shown more consistently positive results. A phase 2/3 trial in newly diagnosed PMR found that about 63 percent of patients on tocilizumab achieved steroid-free remission by week 16, compared with roughly 12 percent on placebo.¹² A systematic review and meta-analysis pooling multiple studies confirmed that tocilizumab significantly reduced both short-term and longer-term relapse rates and lowered cumulative steroid doses.¹³

Tocilizumab is not yet a first-line treatment for PMR in most guidelines, and it comes with its own costs and considerations (it is expensive and given by injection or infusion, and it has side effects including increased infection risk). But for people who are stuck on steroids long-term and accumulating side effects, it represents a real alternative. The evidence here is considerably stronger than for methotrexate, and access is expanding.

The Tapering Pace That Tends to Work

There is no single universal tapering schedule, but the general rhythm is similar across most guidelines. After the initial response at 15 mg, you typically drop relatively quickly to around 10 mg over a few weeks, then more slowly from 10 mg down to 7.5 mg over the next month or two. From there, reductions get smaller and slower. Below 7.5 mg, many doctors reduce by 1 mg at a time, holding at each new dose for four to six weeks before attempting another drop. Below 5 mg, some clinicians go even more cautiously, reducing by 0.5 mg at a time.²

This glacial pace at the lower doses frustrates patients, understandably, but it exists because the relapse zone is between 5 and 7.5 mg, exactly where the finish line seems closest. Going too fast through that range is the most common reason people bounce back up. Researchers who designed tapering protocols for clinical trials acknowledged that even their study schedules were more aggressive than what they would use in routine practice, and recommended a more conservative approach for real-world patients.¹⁴

If you relapse during a taper, the usual approach is to go back up to the last dose at which you felt well (not necessarily all the way back to the starting dose), hold there for a few weeks until things calm down, and then restart the taper at an even slower rate. Every relapse teaches you something about how low your body can go before the inflammation reasserts itself.

What Happens to Your Adrenal Glands After Stopping

One concern that comes up less often but matters greatly is what happens to your body’s ability to produce its own cortisol after months or years of taking synthetic steroids. When you take prednisone, your adrenal glands, which normally produce cortisol, gradually scale back their output because the drug is doing the job for them. After you stop, the glands need time to wake back up. If they do not recover quickly enough, you can develop adrenal insufficiency, where your body cannot mount a proper stress response.

A study that tested adrenal function in patients shortly after stopping prednisolone found that about 2 percent had biochemical evidence of adrenal insufficiency, measured as an inadequate cortisol response on a stimulation test. The affected patients had been treated for 12 to 26 months and were tested within about two to four weeks of their last dose.¹⁵ That 2 percent figure is reassuringly low, but the people it affects can feel terrible: fatigue, weakness, nausea, dizziness, and sometimes outright collapse during physical stress like illness or surgery.

This is one reason the final stages of tapering are done so slowly. The very low doses at the end of a taper, around 1 to 3 mg, are less about controlling PMR inflammation and more about giving the adrenal glands time to resume normal function. Stopping abruptly from even a modest dose like 5 mg can trigger an adrenal crisis in someone whose glands have been suppressed for a long time. If you have been on steroids for more than a few months, always taper under medical supervision rather than stopping on your own.

When PMR Overlaps With Giant Cell Arteritis

About 10 to 20 percent of people with PMR also develop giant cell arteritis (GCA), a related condition that inflames the arteries, particularly in the head and temples. GCA is treated with much higher steroid doses, typically starting at 40 mg of prednisone per day, and patients with visual symptoms may need 60 to 80 mg initially.² The taper for GCA is slower and the total treatment duration often longer than for PMR alone.

If you started with a PMR diagnosis and your steroid dose seems higher or longer than what you read about, one possibility is that your doctor suspects or has confirmed an overlap with GCA. The stakes with GCA are different: untreated, it can cause sudden, permanent vision loss. That urgency justifies the higher doses and more cautious tapering. If your treatment course seems unusually aggressive for “just” PMR, it is worth asking whether GCA is part of the picture.

Monitoring That Matters During Long-Term Treatment

While you are on steroids, your doctor will track blood markers of inflammation, usually ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), along with your symptoms. These markers help guide tapering decisions: if they rise while your dose drops, it signals that the inflammation is returning. However, these tests are not perfect. A small study found that about 14 percent of PMR patients had normal ESR and CRP values even at diagnosis, meaning their inflammation did not show up on the standard tests.¹⁶ For this subgroup, relying heavily on blood markers during tapering can be misleading, and symptom-based decision-making becomes more important.

Beyond inflammation markers, long-term monitoring should include periodic bone density scans (typically every one to two years while on steroids), blood sugar checks for steroid-induced diabetes, blood pressure monitoring, and eye exams for cataracts. Weight and mood should be tracked as well. None of this is optional when treatment stretches past a year, and it often gets underemphasized in primary care compared with specialist rheumatology settings. If your PMR is being managed by a generalist and you are still on steroids after 18 months, consider asking for a rheumatology referral to review the treatment plan.